CSafe, a leading active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, announced today that Emma Lupp has joined its team as vice president, global marketing.

Lupp brings more than 20 years of experience to CSafe, along with a results-focused approach to building global brands that deliver a compelling experience to customers while driving significant business growth and increased market share.

In her new role, Lupp will oversee CSafe’s global marketing activities and work closely with leadership to execute communication strategies that support commercial efforts and company growth goals. Lupp will also play a leading role in developing go-to-market strategies for multiple new product launches in 2024 across CSafe’s robust portfolio of innovative active and passive temperature-controlled shipping solutions for life sciences, cell and gene therapy, military applications and more.

With previous marketing leadership roles across cold chain, automotive, finance, consumer/luxury brand management and media industries, Lupp is a dynamic marketing and business strategist who has most recently transformed a cold chain brand by delivering a substantial increase in engagement and presence across the United States, China and other core international markets.

Based in Zurich, Switzerland, Lupp will be positioned to lead CSafe’s global communication strategies and support the company’s mission to ensure patients around the world receive the medicines and treatments they need.

“As we continue to scale our operations globally, we prioritize impactful communication of our commitment to helping CSafe customers deliver life-enhancing medicines and treatments to patients around the world,” said Patrick Schafer, CEO. “We’re pleased to welcome Emma to our team, where her skills will create exciting opportunities for us to share our mission and comprehensive portfolio of industry-leading cold chain solutions with new and existing markets.”

MONROE, Ohio, September 12, 2023 – CSafe, the largest active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, announced today that Anthony Pishotti has joined the team as Chief Financial Officer (CFO). This expansion of the executive leadership team will accelerate CSafe’s mission to ensure patients around the world receive the medicines and treatments they need. 

Mr. Pishotti brings over 20 years of deep operating, financial, and commercial leadership across the Warehouse Automation, Material Handling, Aircraft Engines, Rail, and Energy industries. He rose through the finance teams at multiple high performing organizations, serving in CFO positions with Honeywell, GE Aviation, and GE Transportation.  A true cross-functional executive, he was most recently the VP of Global Sales at Honeywell International.  In this role he was responsible for a $2 billion warehouse automation business with 100+ global sellers aimed at expanding into new markets, growing share of wallet, and introducing new solution offerings. 

“We are pleased to welcome Anthony to the CSafe team. His experience leading global companies through best-in-class financial planning, commercial operations, and M&A integrations will be invaluable,” said Patrick Schafer, CEO of CSafe. “As we rapidly introduce innovative products and real-time tracking solutions to our active and passive containers, there is no doubt that Anthony’s leadership will accelerate our growth.” 

In this role, Mr. Pishotti will lead the company’s Finance team, guide strategic planning and annual budgeting process, partner with the business on Merger and Acquisition opportunities, and actively support commercial efforts.   

Mr. Schafer added, “CSafe’s commitment to innovation has propelled us into an exciting time for growth. As we continue to deliver comprehensive, high performing solutions for our pharmaceutical customers, we look forward to Anthony’s leadership and support in creating value for all stakeholders.”

MONROE, Ohio, July 11, 2023 – CSafe, the largest provider of a complete range of active and passive temperature-controlled shipping solutions for the pharmaceutical industry, announced today that the company will expand its active bulk air cargo container portfolio to integrate a new -20°C temperature setpoint for the CSafe RKN.

The company will begin offering CSafe RKNs with the new frozen temperature setpoint on the control panel early next year. The CSafe RKN design requires minimal adjustment to accommodate the new -20°C temperature setpoint, limiting the need for additional customer training to take advantage of the new temperate profile.

“Our engineering team designed our RKN in a way that we could easily add frozen temperature setpoints in the future,” said CSafe Chief Operating Officer, Tom Weir. “Every CSafe RKN is built with patented high-performance VIP insulation and an innovative air recirculation system that envelops the entire payload. Combined with our industry-leading preventive maintenance rebuild program and support from our global service network, these technologies and service programs have delivered reliable temperature control and exceptional battery life for 15 years.”

“This expansion of our high-performing active bulk air cargo portfolio is yet another example of CSafe’s on-going commitment to delivering new innovations to meet the changing needs of the biopharma industry,” added CSafe Chief Executive Officer, Patrick Schafer. “We are passionate about ensuring life-saving and life-enhancing medicines can be safely delivered to patients around the world.  With this latest capability, CSafe offers an unmatched range of temperature profiles that can meet virtually every requirement for customers shipping these high-value therapies.”

CSafe RKNs with the -20°C setpoint capability will be available for lease in early 2024. Additional details include:

• Predictive and real-time analysis pre- and post-shipment to assess lane risk based on external data sources, such as flight tracking, inclement weather, etc.;
• total visibility to conditional data in addition battery level percentage and door open/close events;
• sustainable design providing a lower energy active system to maintain optimum performance, while still operating at the broadest RKN ambient operating temperature range in the industry; and
• optimal footprint for all wide-bodied aircraft, ground transportation and warehouse operations.

Monroe, OH -May 22, 2023 – CSafe, the largest provider of a complete range of active and passive temperature-controlled shipping solutions for the pharmaceutical industry, is honored to announce an innovative program for Krystal Biotech that provides the cold chain solution for Krystal’s Vyjuvek gene therapy.

CSafe’s custom thermal shipper for Krystal maintains -20°C throughout the product journey to help ensure that doses of Vyjuvek reach clinicians and patients safely. In addition to best-in-class Vacuum Insulated Panel (VIP) technology, the customized CSafe CGT Ultra solution features simplified product handling.

The Vyjukek supply chain is further optimized by utilizing CSafe’s Retest & Reuse program. This approach features reusable shippers that maintain the highest level of thermal performance. When customers participate in CSafe’s reuse program, our highly qualified team inspects, cleans and thermally requalifies the insulation and shippers to assure thermal integrity prior to reuse. This fully managed, end-to-end solution reduces unnecessary landfill waste and is an efficient, effective, and environmentally responsible packaging program.

“Cell and gene therapies are a core focus for CSafe, and we’re honored to support Krystal Biotech and their transformative treatment,” said Patrick Schafer, CSafe CEO. “Using innovative engineering concepts, the CSafe team is able to stay at the forefront of both biopharmaceutical innovation and sustainability approaches. We’re pleased to support the most advanced therapies with the most advanced solutions for the sustainable, high-performance cold chain.”

Houston, TX and Monroe, OH – May 16, 2023 –  Modality Solutions, a trusted cold chain engineering partner for leading biopharmaceutical companies, and CSafe, the leader in providing a comprehensive suite of thermal shipping solutions for the biopharmaceutical cold chain, announce a strategic partnership to provide a next-generation cold chain solution for cell and gene therapies (CGTs). The integrated end-to-end solution will combine Modality Solution’s pioneering capabilities in cold chain engineering with CSafe’s industry-leading shipping solutions to offer unprecedented predictability, quality, and regulatory compliance to the CGT supply chain. 

The CGT cold chain, the most complex in the history of medicine, carries unprecedented variability and risk that can compromise the product journey, complicate regulatory filings, and jeopardize patient outcomes. Together, Modality Solutions and CSafe have the solutions, systems, and expertise to reduce risk and bring predictability and consistent reliability to the CGT cold chain, ultimately supporting global scale and patient access for these transformative therapies. 

Modality Solutions has supported more than 80 drug approvals in the past three years, with proactive cold chain engineering and validation strategies that have enabled over 300 successful regulatory interactions with more than 45 agencies around the globe. Modality Solutions provides an unrivaled combination of regulatory intelligence, cold chain engineering, and advanced testing capabilities to optimize the cold chain for cell and gene therapies like CAR-T and other regenerative medicines with complex requirements. 

CSafe offers the most comprehensive suite of thermal shipping solutions for the global pharmaceutical cold chain, supporting nearly any shipping temperature profile, payload size and duration. CSafe’s rigorously-tested cold chain solutions have earned a 99.99% reliability rating and have supported the temperature-controlled distribution of more than 6.2 billion doses of COVID-19 vaccine worldwide. CSafe also offers next-generation shipment visability through its CSafe Connect digital ecosystem and TracSafe data logger suite. 

“We’re very excited to be partnering with Modality Solutions,” said Patrick Schafer, CEO, CSafe. “With the science in cell and gene therapies continuing to excel, the real hurdles remain distribution infrastructure and supporting systems. This partnership is a critical step toward providing a solid foundation that the CGT cold chain can rely on and use as a base for scale and worldwide reach.” 

“We partner with world-class companies that are continuously focused on great patient outcomes,” added Gary Hutchinson, President of Modality Solutions. “CSafe has innovative technologies and their focus on the cell and gene therapy supply chain makes them a great fit for us, and more importantly, our clients.” 

Customers seeking more information about the Modality Solutions-CSafe solution for cell and gene therapies and other regenerative medicines are encouraged to contact their Modality Solutions or CSafe business development teams.  

MONROE, Ohio, February 20, 2023 – CSafe, the largest provider of a complete range of active and passive temperature-controlled shipping solutions for the pharmaceutical industry, announced today that Chervee Ho has joined the company as Senior Director of Sales for the Asia Pacific region.

Ms. Ho brings a wealth of experience in business development, marketing and product management in the pharmaceutical, biotech and contract manufacturing sectors. She started her career 20 years ago with Roche and later at Lonza and Vela Diagnostics, holding various positions in product and account management. For the past nine years she has been with Vetter Pharma, most recently as the Head of Asia Pacific.

In her new role at CSafe, Ms. Ho will be responsible for further developing CSafe’s active and passive cold chain packaging business in  the Asia Pacific market and identifying opportunities to expand into new markets throughout the region. She will also lead the APAC commercial team with local representation in Singapore, South Korea, Japan and India.

“In filling this role, we wanted to ensure we found a perfect fit for the business and the APAC team,” noted Seth Hertel, CSafe chief commercial officer. “Chervee is an exceptional communicator, has critical experience working across the various cultures of the region and has deep knowledge of the life science industry, drug development and the pharmaceutical supply chain. I believe she will drive our APAC business and team to new heights in the months and years to come.”

Ms. Ho earned her Bachelor of Science degree in biotechnology, molecular biology and genetic engineering from the Universiti Putra Malaysia and holds a Global Management Certificate from INSEAD Business School. She speaks fluent Mandarin, Cantonese, Bahasa Melayu and English and will be based in Singapore.